.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX16_Tirzepatide.Tirzepatide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX16_Tirzepatide.Tirzepatide| name: | Tirzepatide |
| ATC code: | A10BX16 | route: | subcutaneous |
| n-compartments | 2 |
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist used as a once-weekly injection for the treatment of type 2 diabetes mellitus. It improves glycemic control and can aid in weight reduction. Tirzepatide is clinically approved for use in adults with type 2 diabetes.
Population pharmacokinetics in adults with type 2 diabetes following once-weekly subcutaneous administration across multiple clinical trials; typical subjects with a median age 56 years, both sexes included.
Schneck, K, & Urva, S (2024). Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: pharmacometrics & systems pharmacology 13(3) 494–503. DOI:10.1002/psp4.13099 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38356317
Feng, P, et al., & Cui, Y (2023). A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes. Advances in therapy 40(8) 3434–3445. DOI:10.1007/s12325-023-02536-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37285081